GlassScriptPhysician profile
John Wesley King
NPI 1669465860
$19,276.99
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $5,440 · 2021: $1,212 · 2022: $236.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $18,563.01 | 2019-2021 | |
| Glaxosmithkline, LLC. | $172.89 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $162.12 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $130.06 | 2019-2022 | |
| United Therapeutics Corporation | $66.32 | 2021-2022 | |
| Melinta Therapeutics, LLC | $17.67 | 2020 | |
| Merck Sharp & Dohme LLC | $15.92 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.